On the public citation graph

Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia/ZF2001): A randomized, observer-blinded, placebo-controlled trial

https://doi.org/10.1371/journal.pmed.1003953

0 signed · 74 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.

Claim with ORCID

Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.

See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1002/mco2.110openalex-snapshot

SARS‐CoV‐2 Omicron variant: Characteristics and prevention

inferredcites →https://doi.org/10.1016/j.cell.2022.03.019openalex-snapshot

Neutralizing immunity in vaccine breakthrough infections from the SARS-CoV-2 Omicron and Delta variants

inferredcites →https://doi.org/10.1016/s0140-6736%2821%2902717-3openalex-snapshot

Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial

inferredcites →https://doi.org/10.1016/s0140-6736(20)31208-3openalex-snapshot

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial

inferredcites →https://doi.org/10.1016/s0140-6736(20)31866-3openalex-snapshot

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia

inferredcites →https://doi.org/10.1016/s0140-6736(21)00234-8openalex-snapshot

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

inferredcites →https://doi.org/10.1016/s0140-6736(21)00432-3openalex-snapshot

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

inferredcites →https://doi.org/10.1016/s0140-6736(21)02183-8openalex-snapshot

Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study

inferredcites →https://doi.org/10.1016/s0140-6736(21)02717-3openalex-snapshot

inferredcites →https://doi.org/10.1016/s0140-6736(21)02718-5openalex-snapshot

Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial

inferredcites →https://doi.org/10.1016/s0140-6736(21)02753-7openalex-snapshot

Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial

inferredcites →https://doi.org/10.1016/s1473-3099(21)00127-4openalex-snapshot

Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials

inferredcites →https://doi.org/10.1038/s41422-021-00590-xopenalex-snapshot

Recombinant protein subunit vaccine booster following two-dose inactivated vaccines dramatically enhanced anti-RBD responses and neutralizing titers against SARS-CoV-2 and Variants of Concern

inferredcites →https://doi.org/10.1038/s41586-021-04386-2openalex-snapshot

Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift

inferredcites →https://doi.org/10.1038/s41591-021-01330-9openalex-snapshot

Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study

inferredcites →https://doi.org/10.1038/s41591-021-01377-8openalex-snapshot

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

inferredcites →https://doi.org/10.1038/s41591-021-01540-1openalex-snapshot

Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection

inferredcites →https://doi.org/10.1056/nejmc2119426openalex-snapshot

Effects of a Prolonged Booster Interval on Neutralization of Omicron Variant

inferredcites →https://doi.org/10.1056/nejmoa2104840openalex-snapshot

Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination

inferredcites →https://doi.org/10.1056/nejmoa2105385openalex-snapshot

Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination

inferredcites →https://doi.org/10.1056/nejmoa2116414openalex-snapshot

Homologous and Heterologous Covid-19 Booster Vaccinations

inferredcites →https://doi.org/10.1056/nejmoa2116747openalex-snapshot

Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming

inferredcites →https://doi.org/10.1056/nejmoa2202261openalex-snapshot

Efficacy and Safety of the RBD-Dimer–Based Covid-19 Vaccine ZF2001 in Adults

inferredcites →https://doi.org/10.1093/cid/ciab1041openalex-snapshot

Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant by Sera From BNT162b2 or CoronaVac Vaccine Recipients

inferredcites →https://doi.org/10.1093/cid/ciab845openalex-snapshot

Safety and Immunogenicity of a Recombinant Adenovirus Type-5–Vectored Coronavirus Disease 2019 (COVID-19) Vaccine With a Homologous Prime-Boost Regimen in Healthy Participants Aged ≥6 Years: A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Trial

inferredcites →https://doi.org/10.1126/science.abm0620openalex-snapshot

SARS-CoV-2 vaccine protection and deaths among US veterans during 2021

inferredcites →https://doi.org/10.1126/sciimmunol.abo2202openalex-snapshot

Divergent SARS-CoV-2 Omicron–reactive T and B cell responses in COVID-19 vaccine recipients

inferredcites →https://doi.org/10.15585/mmwr.mm7017e4openalex-snapshot

Updated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients — United States, April 2021

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4174293openalex-extracted

Safety and Efficacy of the Two Doses Conjugated Protein-Based SOBERANA-02 COVID-19 Vaccine and of a Heterologous Three-Dose Combination with SOBERANA-PLUS: Double-Blind, Randomised, Placebo-Controlled Phase 3 Clinical Trial

inferred← citeshttps://doi.org/10.1007/s11356-022-22661-1openalex-snapshot

Current clinical status of new COVID-19 vaccines and immunotherapy

inferred← citeshttps://doi.org/10.1007/s43440-022-00425-5openalex-snapshot

Recent review of COVID-19 management: diagnosis, treatment and vaccination

inferred← citeshttps://doi.org/10.1016/b978-0-443-19170-1.00028-0openalex-snapshot

COVID-19 vaccines: A comprehensive review of safety and efficacy

inferred← citeshttps://doi.org/10.1016/j.azn.2026.02.001openalex-snapshot

A replication-deficient live vaccine candidate against the rabies virus infection in mice

inferred← citeshttps://doi.org/10.1016/j.ebiom.2023.104586openalex-snapshot

Safety and immunogenicity of a modified COVID-19 mRNA vaccine, SW-BIC-213, as a heterologous booster in healthy adults: an open-labeled, two-centered and multi-arm randomised, phase 1 trial

inferred← citeshttps://doi.org/10.1016/j.it.2023.01.005openalex-snapshot

COVID-19 vaccines and a perspective on Africa

inferred← citeshttps://doi.org/10.1016/j.lana.2022.100423openalex-snapshot

Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA-Plus: a double-blind, randomised, placebo-controlled phase 3 clinical trial

inferred← citeshttps://doi.org/10.1016/j.lanwpc.2023.100829openalex-snapshot

Immunogenicity and safety of heterologous immunisation with Ad5-nCOV in healthy adults aged 60 years and older primed with an inactivated SARS-CoV-2 vaccine (CoronaVac): a phase 4, randomised, observer-blind, non-inferiority trial

inferred← citeshttps://doi.org/10.1016/j.mtbio.2025.102583openalex-snapshot

Enhanced oral nanomedicine utilizing biomineralized oncolytic virus for synergistic gastrointestinal cancer therapy

inferred← citeshttps://doi.org/10.1016/j.vaccine.2023.09.013openalex-snapshot

An overview of protein-based SARS-CoV-2 vaccines

inferred← citeshttps://doi.org/10.1021/acs.molpharmaceut.5c00470openalex-snapshot

Choline-Retinoic Acid Ionic Liquid [Cho][Ra] as Potential Adjuvant to Enhance Humoral, Cellular, and Mucosal Immune Responses of SARS-CoV-2 RBD Antigen

inferred← citeshttps://doi.org/10.1038/s41467-023-40489-2openalex-snapshot

Safety and immunogenicity of Ad5-nCoV immunization after three-dose priming with inactivated SARS-CoV-2 vaccine in Chinese adults

inferred← citeshttps://doi.org/10.1038/s41541-025-01280-0openalex-snapshot

Advances and prospects of respiratory mucosal vaccines: mechanisms, technologies, and clinical applications

inferred← citeshttps://doi.org/10.1080/14760584.2022.2119133openalex-snapshot

Batch-to-batch consistency trial of an adenovirus type-5 vector-based COVID-19 vaccine in adults aged 18 years and above

inferred← citeshttps://doi.org/10.1080/14760584.2023.2242528openalex-snapshot

A China-developed adenovirus vector-based COVID-19 vaccine: review of the development and application of Ad5-nCov

inferred← citeshttps://doi.org/10.1080/14760584.2023.2274491openalex-snapshot

Safety, immunogenicity and immune-persistence of heterologous prime-boost immunization with BBIBP-CorV and ZF2001 against SARS-CoV-2 in healthy adults aged 18 years or older

inferred← citeshttps://doi.org/10.1080/14760584.2024.2315089openalex-snapshot

Comparing reactogenicity of COVID-19 vaccine boosters: a systematic review and meta-analysis

inferred← citeshttps://doi.org/10.1080/21645515.2023.2194189openalex-snapshot

Effectiveness of a booster dose of COVID-19 vaccines during an outbreak of SARS-CoV-2 Omicron BA.2.2 in China: A case–control study

inferred← citeshttps://doi.org/10.1080/21645515.2025.2591504openalex-snapshot

Immunogenicity of a recombinant subunit COVID-19 vaccine: A prospective, multi-centre, longitudinal study in Chinese Alzheimer’s disease patients

inferred← citeshttps://doi.org/10.1089/vim.2024.0076openalex-snapshot

Maintenance of Long-Term Effective Humoral Immune Response in Patients with COVID-19 with Homologous or Heterologous Booster Vaccines: A Retrospective Study

inferred← citeshttps://doi.org/10.1093/lifemeta/load019openalex-snapshot

Safety and immunogenicity of a modified COVID-19 mRNA vaccine, SYS6006, as a fourth-dose booster following three doses of inactivated vaccines in healthy adults: an open-labeled Phase 1 trial

inferred← citeshttps://doi.org/10.1128/jvi.01129-23openalex-snapshot

Recombinant parainfluenza virus 5 expressing clade 2.3.4.4b H5 hemagglutinin protein confers broad protection against H5Ny influenza viruses

inferred← citeshttps://doi.org/10.1128/jvi.01989-24openalex-snapshot

Efficacy of parainfluenza virus 5 (PIV5)-vectored intranasal COVID-19 vaccine as a single dose primer and booster against SARS-CoV-2 variants

inferred← citeshttps://doi.org/10.1128/mmbr.00260-24openalex-snapshot

Molecular mechanisms of SARS-CoV-2 entry: implications for biomedical strategies

inferred← citeshttps://doi.org/10.1186/s12916-023-02942-3openalex-snapshot

Neutralizing antibody levels associated with injectable and aerosolized Ad5-nCoV boosters and BA.2 infection

inferred← citeshttps://doi.org/10.1186/s12967-026-08620-1openalex-snapshot

Systemic immune profiling of heterologous versus homologous boosting of COVID-19 vaccination

inferred← citeshttps://doi.org/10.1186/s12982-024-00364-xopenalex-snapshot

Key insights into recent advances and challenges in COVID-19 management

inferred← citeshttps://doi.org/10.1371/journal.pmed.1004051openalex-snapshot

Facilitating preprint sharing in the health sciences

inferred← citeshttps://doi.org/10.1371/journal.pone.0283473openalex-snapshot

Immunogenicity of a spike protein subunit-based COVID-19 vaccine with broad protection against various SARS-CoV-2 variants in animal studies

inferred← citeshttps://doi.org/10.1371/journal.ppat.1011744openalex-snapshot

Immunogenicity and safety of heterologous boost immunization with PastoCovac Plus against COVID-19 in ChAdOx1-S or BBIBP-CorV primed individuals

inferred← citeshttps://doi.org/10.2139/ssrn.4807155openalex-snapshot

Real-Word Immunogenicity of a Recombinant Subunit COVID-19 Vaccine and Effectiveness Against Omicron Infection: A Prospective, Multi-Centre, Longitudinal Cohort Study in Alzheimer's Disease Patients

inferred← citeshttps://doi.org/10.2174/0113892037274719231212044235openalex-snapshot

Global Emergence of SARS-CoV2 Infection and Scientific Interventions to Contain its Spread

inferred← citeshttps://doi.org/10.2196/47272openalex-snapshot

Immune-Boosting Effect of the COVID-19 Vaccine: Real-World Bidirectional Cohort Study

inferred← citeshttps://doi.org/10.3389/978-2-8325-4116-6openalex-snapshot

The Covid-19 and TB Syndemic: Differences and Similarities

inferred← citeshttps://doi.org/10.3389/fcimb.2025.1548787openalex-snapshot

Repeated-dose toxicity and immunogenicity evaluation of a recombinant subunit COVID-19 vaccine (ZF2001) in rats

inferred← citeshttps://doi.org/10.3389/fimmu.2022.1011484openalex-snapshot

A vaccine based on the yeast-expressed receptor-binding domain (RBD) elicits broad immune responses against SARS-CoV-2 variants

inferred← citeshttps://doi.org/10.3389/fimmu.2023.1273938openalex-snapshot

Vaccine development against tuberculosis before and after Covid-19

inferred← citeshttps://doi.org/10.3389/fpubh.2023.1143790openalex-snapshot

Vaccine research and development capacity in Central and West Asia: A path toward sustainable vaccine R&D programs

inferred← citeshttps://doi.org/10.3390/biom13111565openalex-snapshot

An Overview of SARS-CoV-2 Etiopathogenesis and Recent Developments in COVID-19 Vaccines

inferred← citeshttps://doi.org/10.3390/ijms232315415openalex-snapshot

COVID-19 Vaccines, Effectiveness, and Immune Responses

inferred← citeshttps://doi.org/10.3390/vaccines12091002openalex-snapshot

Novel Administration Routes, Delivery Vectors, and Application of Vaccines Based on Biotechnologies: A Review

inferred← citeshttps://doi.org/10.3390/vaccines13040338openalex-snapshot

Decade-Long Sustained Cellular Immunity Induced by Sequential and Repeated Vaccination with Four Heterologous HIV Vaccines in Rhesus Macaques

inferred← citeshttps://doi.org/10.3892/mmr.2022.12779openalex-snapshot

Lessons from SARS‑CoV‑2 and its variants (Review)

inferred← citeshttps://doi.org/10.4108/eetpht.10.5571openalex-snapshot

Rule Based Mamdani Fuzzy Inference System to Analyze Efficacy of COVID19 Vaccines

inferred← citeshttps://doi.org/10.6084/m9.figshare.23621392openalex-snapshot

Additional file 1 of Neutralizing antibody levels associated with injectable and aerosolized Ad5-nCoV boosters and BA.2 infection

Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.